Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 165.80M P/E 105.33 EPS this Y -17.40% Ern Qtrly Grth -
Income -71.58M Forward P/E -11.92 EPS next Y -25.40% 50D Avg Chg 39.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 122.00%
Dividend N/A Price/Book 1.84 EPS next 5Y - 52W High Chg -
Recommedations 1.70 Quick Ratio 9.78 Shares Outstanding 47.01M 52W Low Chg 549.00%
Insider Own 6.93% ROA -28.94% Shares Float 19.54M Beta -
Inst Own 78.44% ROE -44.90% Shares Shorted/Prior 4.64M/4.33M Price 6.32
Gross Margin - Profit Margin - Avg. Volume 117,086 Target Price 34.33
Oper. Margin - Earnings Date May 9 Volume 271,721 Change 15.96%
About IMARA Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

IMARA Inc. News
04/19/24 MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
04/11/24 Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
04/11/24 Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
04/09/24 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
04/09/24 Owning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),
03/28/24 Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
03/23/24 Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares
03/19/24 Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
03/14/24 Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
02/27/24 Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
01/03/24 Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares
11/09/23 Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
08/17/23 7 A-Rated Biotech Stocks for Your August Buy List
08/10/23 Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
05/31/23 Enliven Therapeutics to Present at Two Upcoming Investor Conferences
05/11/23 Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
ELVN Chatroom

User Image shared_alerts Posted - 3 days ago

-05/03/2024- πŸ“‰ SCANNER UPDATEπŸ“ˆ $GME $ENVX $ELVN $SMR ↩️

User Image insiderbuyingselling Posted - 4 days ago

$ELVN new insider selling: 12000 shares. http://insiderbuyingselling.com/?t=ELVN

User Image insiderbuyingselling Posted - 04/29/24

$ELVN new insider selling: 12000 shares. http://insiderbuyingselling.com/?t=ELVN

User Image _www_larval_com_ Posted - 04/19/24

$WISA -6%[5%] $SERV 6%[-2%] $EDBL 5%[-14%] $YYAI 4%[-54%] $ELVN 4%[0%] most notable movement into the final minutes of trading.

User Image DonCorleone77 Posted - 04/18/24

$ELVN Enliven files to sell 6.43M shares of common stock for holders

User Image insiderbuyingselling Posted - 04/15/24

$ELVN new insider selling: 20000 shares. http://insiderbuyingselling.com/?t=ELVN

User Image insiderbuyingselling Posted - 04/15/24

$ELVN new insider selling: 30000 shares. http://insiderbuyingselling.com/?t=ELVN

User Image insiderbuyingselling Posted - 04/15/24

$ELVN new insider selling: 14000 shares. http://insiderbuyingselling.com/?t=ELVN

User Image insiderbuyingselling Posted - 04/12/24

$ELVN new insider selling: 67000 shares. http://insiderbuyingselling.com/?t=ELVN

User Image fallondpicks Posted - 04/11/24

19 #stockbreakouts $ELVN (gap), $INFA, $RELL (gap), $SII. Two sub-$1, three $1-2.

User Image _www_larval_com_ Posted - 04/11/24

$ELVN has reverted -4% lower to 18% (~3Mv) in the last few minutes, 04/19 options, follow for more volatility.

User Image tradingtwenty Posted - 04/11/24

$ELVN has trended 11 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 11, 2024 07:55 AM: Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid.. Link: https://tradingtwenty.com/news/425641/enliven-therapeutics-announces-positive-proof-of-concept-data-from-phase-1-clinical-trial-of-elvn-001-in-chronic-myeloid-leukemia

User Image PensionPulse Posted - 04/11/24

$ELVN this biotech ticker is doing better than $ENLV today...

User Image ANTHONYMOMO Posted - 04/11/24

$ELVN TPET .25 the cheapest and thinnest oil stock exploding like ELVN

User Image _www_larval_com_ Posted - 04/11/24

$ADIL 11%[16%] $JANX 6%[20%] $SPRC 6%[14%] $BSGM -5%[3%] $ELVN 5%[27%] most notable movement within the first minutes of trading.

User Image ClassifiedTrades Posted - 04/11/24

$CADL quick 1st target so far, stops moved no way to loose $ELVN $ELYM

User Image shared_alerts Posted - 04/11/24

-04/11/2024- πŸ“‰ SCANNER UPDATEπŸ“ˆ $OMER $DM $ELVN $CRK ↩️

User Image Stock_Titan Posted - 04/11/24

$ELVN Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia https://www.stocktitan.net/news/ELVN/enliven-therapeutics-announces-positive-proof-of-concept-data-from-kmvwzhqszg55.html

User Image insiderbuyingselling Posted - 04/10/24

$ELVN new insider selling: 4875 shares. http://insiderbuyingselling.com/?t=ELVN

User Image insiderbuyingselling Posted - 1 month ago

$ELVN new insider selling: 3237 shares. http://insiderbuyingselling.com/?t=ELVN

User Image insiderbuyingselling Posted - 03/29/24

$ELVN new insider selling: 3250 shares. http://insiderbuyingselling.com/?t=ELVN

User Image DonCorleone77 Posted - 03/28/24

$ELVN Enliven to share initial proof of concept data from ELVN-001 Phase 1 trial Enliven Therapeutics "announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape. ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML."

User Image Stock_Titan Posted - 03/28/24

$ELVN Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 https://www.stocktitan.net/news/ELVN/enliven-therapeutics-to-share-initial-proof-of-concept-data-from-xjh3yj4ydy8y.html

User Image Fullratio Posted - 03/20/24

$ELVN debt is 100% less than its equity: https://fullratio.com/stocks/nasdaq-elvn/enliven-therapeutics

User Image tradingtwenty Posted - 03/19/24

Top 5 stock gainers today that have trended in the past 24 hours: $OTRK 131.58% πŸ”₯ $FUSN 99.06% $WORX 53.51% $PDYN 40.38% $ELVN 38.77% Link: https://tradingtwenty.com/dashboard/trending/past

User Image Stocksrunner Posted - 03/19/24

πŸš€ Its Tantalizing with the market buzzing! Let's dive into the action! πŸ’₯ $ELVN just announced a massive $90 million private placement, fueling excitement and extending their runway into late 2026! πŸ“ˆ Join us on April 11th for a discussion on groundbreaking trial data! πŸ’Ό $SPIR is skyrocketing with a collaboration that's set to revolutionize weather prediction! πŸŒͺ️ Get ready to ride the wave of innovation with Spire Global and NVIDIA! 🌐 $CRNX is on fire πŸ”₯ as their lead drug hits the mark in late-stage trials, promising hope for patients and profits for investors! πŸ’Š Don't miss out on this bullish momentum! πŸ“Š And let's not forget $HOTH, where groundbreaking research is unlocking new possibilities in Alzheimer's treatment! 🧠 Get in early on this game-changing therapy! πŸš€ Stay tuned for more updates throughout the day! The market waits for no one! πŸ’ΌπŸ’°

User Image VrtcIl Posted - 03/19/24

$ELVN is currently achieving new intraday highs, showing a bullish momentum on the technical charts. How far can this thing run guys? Price: 17.71 Float: 19.4M Short Float: 20.4 % πŸ’° Dollar Volume: 38.4K ℹ️ USA | Biotechnology

User Image Call_Me_Put Posted - 03/19/24

$ELVN Trading at $17.40 after a $90MM private placement priced at $14. Low borrow rate but HTB, going to put out a locate request.

User Image _StockTrader Posted - 03/19/24

Real-Time Stock Data $ELVN Price: 19.18 Volume: 435923 Market Cap: 701255232 PE Ratio: -5.729729 Powered by: OZSC

User Image VrtcIl Posted - 03/19/24

Trail your stops on $ELVN to secure profits. Consider strategic placement below prior pivot lows on the technical chart to secure gains and manage potential downside risks effectively. Price: 16.96 Float: 19.4M Short Float: 20.4 % πŸ’° Dollar Volume: 224.1K ℹ️ USA | Biotechnology

Analyst Ratings
Mizuho Buy Apr 9, 24
Jefferies Buy Mar 29, 23
TD Cowen Outperform Mar 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Heyman Richard A. Director Director Jan 30 Sell 16.4091 1,270 20,840 146,010 02/01/24
Lyssikatos Joseph P CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Jan 29 Sell 15.85 12,000 190,200 01/31/24
Lyssikatos Joseph P CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Jan 29 Option 1.12 12,000 13,440 12,000 01/31/24
Hohl Benjamin CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jan 29 Sell 15.81 3,250 51,382 01/31/24
Hohl Benjamin CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jan 29 Option 2.48 3,250 8,060 3,250 01/31/24
Kintz Samuel President and CEO President and CEO Jan 25 Sell 15.41 12,000 184,920 01/29/24
Kintz Samuel President and CEO President and CEO Jan 25 Option 1.12 12,000 13,440 12,000 01/29/24
Patel Anish Chief Operating Offi.. Chief Operating Officer Jan 22 Sell 15.135 4,875 73,783 17,222 01/24/24
Lyssikatos Joseph P Chief Scientific Off.. Chief Scientific Officer Dec 29 Sell 14.45 12,000 173,400 01/03/24
Lyssikatos Joseph P Chief Scientific Off.. Chief Scientific Officer Dec 29 Option 1.12 12,000 13,440 12,000 01/03/24
Patel Anish Chief Operating Offi.. Chief Operating Officer Dec 28 Sell 15.03 13,540 203,506 22,097 01/02/24
Hohl Benjamin Chief Financial Offi.. Chief Financial Officer Dec 28 Sell 15.03 11,870 178,406 01/02/24
Hohl Benjamin Chief Financial Offi.. Chief Financial Officer Dec 28 Option 2.48 11,870 29,438 9,383 01/02/24
Patel Anish Chief Operating Offi.. Chief Operating Officer Dec 22 Sell 15.02 1,085 16,297 35,637 12/27/23
Hohl Benjamin Chief Financial Offi.. Chief Financial Officer Dec 22 Sell 15.04 1,130 16,995 12/27/23
Hohl Benjamin Chief Financial Offi.. Chief Financial Officer Dec 22 Option 2.48 1,130 2,802 100 12/27/23
Lyssikatos Joseph P Chief Scientific Off.. Chief Scientific Officer Dec 21 Sell 13.03 6,566 85,555 12/26/23
Lyssikatos Joseph P Chief Scientific Off.. Chief Scientific Officer Dec 21 Option 1.12 6,566 7,354 6,546 12/26/23
Kintz Samuel President and CEO President and CEO Dec 21 Sell 13.02 8,195 106,699 12/26/23
Kintz Samuel President and CEO President and CEO Dec 21 Option 1.12 8,195 9,178 8,175 12/26/23
Heyman Richard A. Director Director Dec 21 Sell 13 216 2,808 29,216 12/26/23
Lyssikatos Joseph P Chief Scientific Off.. Chief Scientific Officer Sep 29 Sell 13.62 12,000 163,440 10/03/23
Lyssikatos Joseph P Chief Scientific Off.. Chief Scientific Officer Sep 29 Option 1.12 12,000 13,440 12,000 10/03/23
Kintz Samuel President and CEO President and CEO Sep 25 Option 1.12 12,000 13,440 12,000 09/26/23
Kintz Samuel President and CEO President and CEO Sep 25 Sell 13.81 12,000 165,720 09/26/23
GRAY MICHAEL CFO & COO CFO & COO Feb 22 Sell 4.67 9,856 46,028 27,610 02/22/23
Ballal Rahul D. Chief Executive Offi.. Chief Executive Officer Feb 22 Sell 4.66 32,861 153,132 87,835 02/22/23
GRAY MICHAEL CFO & COO CFO & COO Jan 30 Sell 3.92 3,596 14,096 37,466 02/01/23
Ballal Rahul D. Chief Executive Offi.. Chief Executive Officer Jan 30 Sell 3.91 11,313 44,234 120,696 02/01/23
Leonard Braden Michael 10% Owner 10% Owner Jan 03 Sell 4.00 1,250,000 5,000,000 1,767,774 01/05/23
Leonard Braden Michael 10% Owner 10% Owner Dec 30 Sell 4.04 20,000 80,800 230,000 12/30/22
Leonard Braden Michael 10% Owner 10% Owner Dec 28 Sell 4.04 20,000 80,800 250,000 12/29/22
Leonard Braden Michael 10% Owner 10% Owner Dec 22 Sell 4.06 50,000 203,000 270,000 12/27/22
Leonard Braden Michael 10% Owner 10% Owner Jun 16 Buy 1.1087 83,199 92,243 3,017,774 06/21/22
Leonard Braden Michael 10% Owner 10% Owner May 16 Buy 1.21 41,145 49,785 2,901,145 05/18/22
Leonard Braden Michael 10% Owner 10% Owner Apr 21 Buy 1.39 560,000 778,400 2,860,000 04/25/22
New Enterprise Associates 14,... 10% Owner 10% Owner Apr 05 Sell 1.09 694,551 757,061 2,611,050 04/07/22
MOTT DAVID M Director Director Feb 18 Buy 1.44 151,472 218,120 229,224 02/23/22
MOTT DAVID M Director Director Feb 15 Buy 1.19 45,926 54,652 77,752 02/17/22
MOTT DAVID M Director Director Feb 10 Buy 1.23 31,826 39,146 31,826 02/14/22
New Enterprise Associates 14,... 10% Owner 10% Owner Jan 21 Sell 1.56 134,558 209,910 3,305,601 01/25/22
New Enterprise Associates 14,... 10% Owner 10% Owner Jan 18 Sell 1.84 26,555 48,861 3,440,159 01/20/22
New Enterprise Associates 14,... 10% Owner 10% Owner Jan 12 Sell 1.95 21,550 42,022 3,466,714 01/14/22
New Enterprise Associates 14,... 10% Owner 10% Owner Jan 07 Sell 2.04 18,760 38,270 3,488,264 01/11/22
New Enterprise Associates 14,... 10% Owner 10% Owner Jan 04 Sell 2.25 31,916 71,811 3,507,024 01/06/22
New Enterprise Associates 14,... 10% Owner 10% Owner Dec 27 Sell 2.35 67,427 158,453 3,655,416 12/29/21
Ballal Rahul D. Chief Executive Offi.. Chief Executive Officer Dec 21 Option 3.15 4,999 15,747 4,999 12/21/20
Ballal Rahul D. Chief Executive Offi.. Chief Executive Officer Dec 21 Sell 25 4,999 124,975 12/21/20